happening now with whole-genome sequencing? What are the goals in near/ long term?—Define productive pathways.

Andrew Conrad: Chief Scientific Officer, LabCorp’s NGI

Kathy Giusti: Founder and Chief Executive Officer, Multiple Myeloma Research Foundation (MMRF)

Panel discussion: ~30 min

11:00 AM

SESSION 3: BEYOND THE GENOME—INFORMATION FOR A NEW TAXONOMY

A panel discussion—Manuel Llinas, Moderator

In addition to genome sequence, other information could be leveraged to improve health and research as part of a New Taxonomy of Disease Network. What information could/ should be included in the network? Would this enable longitudinal studies?

Lewis Cantley: Chief, Division of Signal Transduction, Harvard Medical School—Metabolome, proteome

Martin Blaser:Frederick H. King Professor of Internal Medicine and Chairman of the Department of Medicine, NYU School of Medicine—Microbiome

Jason Lieb: Professor, Department of Biology, UNC—Epigenetics; ENCODE project

Helmut Zarbl: UMDNJ-Robert Wood Johnson Medical School, Environmental & Occupational Medicine, Rutgers University—Environmental Health, toxicology

Erin Ramos: Epidemiologist, National Human Genome Research Institute—Sociological contributions, PhenX

Panel discussion: ~30 min

12:45 PM

Lunch

1:30 PM

SESSION 4: ETHICS AND PRIVACY

A panel discussion—Bernie Lo, Moderator

Alta Charo: Professor of Law and Bioethics, University of Wisconsin Law School—Informed Consent, Privacy

Sanford Schwartz: Professor of Medicine, Health Care Management, and Economics, University of Pennsylvania—Clinical validation issues

Debra Lappin: President, Council for American Medical Innovation—Patient Advocate



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement